The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

The impact of different first-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)s to the clinical efficacy of osimertinib in EGFR-mutant non-small-cell lung cancer (NSCLC) patients with acquired T790M was still unclear. We enrolled 733 advanced EGFR-mutant NSCLC patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yen-Hsiang, Tseng, Jeng-Sen, Hsu, Kuo-Hsuan, Chen, Kun-Chieh, Su, Kang-Yi, Yu, Sung-Liang, Chen, Jeremy J. W., Yang, Tsung-Ying, Chang, Gee-Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187359/
https://www.ncbi.nlm.nih.gov/pubmed/34103652
http://dx.doi.org/10.1038/s41598-021-91657-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187359/
https://www.ncbi.nlm.nih.gov/pubmed/34103652
http://dx.doi.org/10.1038/s41598-021-91657-7

Ejemplares similares